Drug Trial News

RSS

New triplet therapies show promise for relapsed and newly diagnosed leukemias

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias.

9 Dec 2024

First-in-class monoclonal antibody shows promise for rare, aggressive hyperinflammatory condition

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.

9 Dec 2024

Novel drug combination shows promise for CLL treatment

A novel, fixed-duration drug combination - consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug - shows deep and durable responses in patients with chronic lymphocytic leukemia (CLL), Dana-Farber Cancer Institute investigator Jennifer Brown, MD, PhD, reports at the 66th American Society for Hematology (ASH) Annual Meeting and Exposition, on behalf of the trial investigators.

9 Dec 2024

Antibody trials show encouraging results in patients with high-risk forms of two blood cancers

Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.

9 Dec 2024

Breakthrough treatment improves survival rates for children with B-ALL

Just days before his fourth birthday, Santiago was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL), the most common cancer in children.

9 Dec 2024

Filgotinib offers new promise for managing Crohn’s disease

Filgotinib, a JAK1 preferential inhibitor, shows promise as an effective and well-tolerated maintenance therapy for Crohn's disease, achieving clinical and endoscopic remission in phase 3 trials. The findings highlight its potential as a novel therapeutic option for difficult-to-treat patients.

8 Dec 2024

Phase one trial explores novel immunotherapy for breast cancer

A groundbreaking phase one clinical trial exploring a novel cell-based immunotherapy for breast cancer has been accepted for publication in JAMA Oncology.

5 Dec 2024

L-arginine shows potential in treating spinocerebellar ataxia type 6

A team led by Specially Appointed Associate Professor Tomohiko Ishihara and Professor Osamu Onodera at Niigata University, along with Professor Yoshitaka Nagai at Kindai University, conducted a randomized, double-blind trial on the efficacy and safety of L-arginine in treating Spinocerebellar ataxia type 6 (SCA6).

3 Dec 2024

Concizumab shows promising results for hemophilia patients

For people with the bleeding disorder hemophilia, life can seem like one continuous state of alertness. If they accidentally cut their finger while chopping vegetables, they have to immediately administer the clotting factor protein that their body either lacks or does not produce enough of.

2 Dec 2024

New injection treatment could be a game-changer for people with asthma and COPD

An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%.

27 Nov 2024

First U.S. trial uses non-viral CRISPR to correct sickle cell mutation

UCSF Benioff Children's Hospital Oakland is enrolling patients in an innovative clinical trial that seeks to cure sickle cell disease.

26 Nov 2024

Tirzepatide cuts diabetes risk by 90% in obese patients, study shows

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to the results of a new study led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, Yale School of Medicine and other institutions.

26 Nov 2024

Temozolomide and radiation combination improves survival in low-grade glioma patients

Both radiation and temozolomide, a generic chemotherapy treatment in pill form, have meaningful single-modality anti-tumor activity against slow-growing, low-grade gliomas.

25 Nov 2024

Cetuximab performs better than durvalumab in treating head and neck cancers

Head and neck cancers are the seventh most common type of cancer worldwide, according to the 2020 World Cancer Report. Smokers and drinkers, as well as those with HPV infections, are disproportionately affected.

22 Nov 2024

Titrzepatide reduces risk of death or worsening heart failure for patients with obesity-related heart failure

Weight-loss and diabetes drug tirzepatide can reduce the risk of death or worsening heart failure for patients with heart failure, preserved heart pump function and obesity, new research from UVA Health reveals.

21 Nov 2024

Oral medication sodium oxybate shows promise for treating laryngeal dystonia

Laryngeal dystonia (LD), a rare neurological disease that significantly impacts a person's ability to speak due to uncontrollable vocal cord spasms, can have a debilitating effect on a person's social life, employment and mental health.

20 Nov 2024

CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis

A new type of therapy that 'edits' a gene in patients with a rare heart condition has been shown to be safe and effective, according to research from UCL and the Royal Free Hospital.

20 Nov 2024

Muvalaplin shows promise in lowering Lp(a) levels in clinical trial

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

19 Nov 2024

New nasal spray form of bumetanide shows promise for heart failure treatment

A new nasal spray form of the medication bumetanide may reduce the tissue swelling caused by heart failure as effectively as the standard oral and intravenous formulations of the medication, according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

19 Nov 2024

Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients

Results from a randomized phase 2 clinical trial show that adding high-dose, intravenous (IV) vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer from eight months to 16 months.

19 Nov 2024